Clinical Trial: Brostallicin or Doxorubicin as First-Line Therapy in Treating Patients With Relapsed, Refractory, or Metastatic Soft Tissue Sarcoma

Study Status: Active, not recruiting
Recruit Status: Unknown status
Study Type: Interventional

Official Title: Randomized Phase II Study of Brostallicin (PNU-166196A) Versus Doxorubicin as First Line Chemotherapy in Patients With Advanced or Metastatic Soft Tissue Sarcoma

Brief Summary:

RATIONALE: Drugs used in chemotherapy, such as brostallicin and doxorubicin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.

PURPOSE: This randomized phase II trial is studying the side effects and how well brostallicin or doxorubicin works as first-line therapy in treating patients with relapsed, refractory, or metastatic soft tissue sarcoma.


Detailed Summary:

OBJECTIVES:

Primary

  • Determine the activity and safety of brostallicin vs doxorubicin hydrochloride as first-line therapy in patients with relapsed, refractory, or metastatic soft tissue sarcoma.

OUTLINE: This is a randomized, multicenter study. Patients are stratified according to participating and age(younger than 60 years vs 60 years and over). Patients are randomized to 1 of 2 treatment arms.

  • Arm I: Patients receive brostallicin IV over 10 minutes on day 1.
  • Arm II: Patients receive doxorubicin hydrochloride IV over 10 minutes on day 1. In both arms, treatment repeats every 3 weeks for up to 6 courses in the absence of disease progression or unacceptable toxicity.

After completion of study treatment, patients are followed at 30 days and then every 12 weeks thereafter.

PROJECTED ACCRUAL: A total of 108 patients will be accrued for this study.


Sponsor: European Organisation for Research and Treatment of Cancer - EORTC

Current Primary Outcome: Six-month progression-free survival, in terms of complete response, partial response, or no change

Original Primary Outcome: Six month progression-free survival, defined in terms of complete response, partial response, or no change

Current Secondary Outcome:

  • Overall progression-free survival
  • Objective tumor response
  • Safety (CTCAE v 3.0)
  • Duration of response
  • Overall survival


Original Secondary Outcome: Same as current

Information By: European Organisation for Research and Treatment of Cancer - EORTC

Dates:
Date Received: December 11, 2006
Date Started: October 2006
Date Completion:
Last Updated: August 7, 2014
Last Verified: July 2010